Treatment With Updated FDC Of Rifampicin/Isoniazid/Pyrazinamide May Decrease Risk For Insufficient Exposure To Rifampicin Among Children With TB, Study Indicates

November 15, 2021

Infectious Disease Advisor (11/12, Mermelstein) reported, “Treatment with an updated fixed-dose combination (FDC) of rifampicin/isoniazid/ pyrazinamide may decrease the risk for insufficient exposure to rifampicin among children with tuberculosis (TB) inf...